Directing mesenchymal stem cells to bone to augment bone formation and increase bone mass

Min Guan, Wei Yao, Ruiwu Liu, Kit Lam, Jan Nolta, Junjing Jia, Brian Panganiban, Liping Meng, Ping Zhou, Mohammad Shahnazari, Robert O. Ritchie, Nancy E Lane

Research output: Contribution to journalArticle

148 Citations (Scopus)

Abstract

Aging reduces the number of mesenchymal stem cells (MSCs) that can differentiate into osteoblasts in the bone marrow, which leads to impairment of osteogenesis. However, if MSCs could be directed toward osteogenic differentiation, they could be a viable therapeutic option for bone regeneration. We have developed a method to direct MSCs to the bone surface by attaching a synthetic high-affinity and specific peptidomimetic ligand (LLP2A) against integrin α4β1 on the MSC surface to a bisphosphonate (alendronate, Ale) that has a high affinity for bone. LLP2A-Ale induced MSC migration and osteogenic differentiation in vitro. A single intravenous injection of LLP2A-Ale increased trabecular bone formation and bone mass in both xenotransplantation studies and in immunocompetent mice. Additionally, LLP2A-Ale prevented trabecular bone loss after peak bone acquisition was achieved or as a result of estrogen deficiency. These results provide proof of principle that LLP2A-Ale can direct MSCs to the bone to form new bone and increase bone strength.

Original languageEnglish (US)
Pages (from-to)456-462
Number of pages7
JournalNature Medicine
Volume18
Issue number3
DOIs
StatePublished - Mar 2012

Fingerprint

Alendronate
Stem cells
Mesenchymal Stromal Cells
Osteogenesis
Bone
Bone and Bones
Peptidomimetics
Heterologous Transplantation
Bone Regeneration
Diphosphonates
Osteoblasts
Integrins
Intravenous Injections
Cell Movement
Estrogens
Bone Marrow
Ligands
Cancellous Bone
Aging of materials

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Directing mesenchymal stem cells to bone to augment bone formation and increase bone mass. / Guan, Min; Yao, Wei; Liu, Ruiwu; Lam, Kit; Nolta, Jan; Jia, Junjing; Panganiban, Brian; Meng, Liping; Zhou, Ping; Shahnazari, Mohammad; Ritchie, Robert O.; Lane, Nancy E.

In: Nature Medicine, Vol. 18, No. 3, 03.2012, p. 456-462.

Research output: Contribution to journalArticle

Guan, Min ; Yao, Wei ; Liu, Ruiwu ; Lam, Kit ; Nolta, Jan ; Jia, Junjing ; Panganiban, Brian ; Meng, Liping ; Zhou, Ping ; Shahnazari, Mohammad ; Ritchie, Robert O. ; Lane, Nancy E. / Directing mesenchymal stem cells to bone to augment bone formation and increase bone mass. In: Nature Medicine. 2012 ; Vol. 18, No. 3. pp. 456-462.
@article{fd0d41bd80b14223ae644b2ccd3d47c6,
title = "Directing mesenchymal stem cells to bone to augment bone formation and increase bone mass",
abstract = "Aging reduces the number of mesenchymal stem cells (MSCs) that can differentiate into osteoblasts in the bone marrow, which leads to impairment of osteogenesis. However, if MSCs could be directed toward osteogenic differentiation, they could be a viable therapeutic option for bone regeneration. We have developed a method to direct MSCs to the bone surface by attaching a synthetic high-affinity and specific peptidomimetic ligand (LLP2A) against integrin α4β1 on the MSC surface to a bisphosphonate (alendronate, Ale) that has a high affinity for bone. LLP2A-Ale induced MSC migration and osteogenic differentiation in vitro. A single intravenous injection of LLP2A-Ale increased trabecular bone formation and bone mass in both xenotransplantation studies and in immunocompetent mice. Additionally, LLP2A-Ale prevented trabecular bone loss after peak bone acquisition was achieved or as a result of estrogen deficiency. These results provide proof of principle that LLP2A-Ale can direct MSCs to the bone to form new bone and increase bone strength.",
author = "Min Guan and Wei Yao and Ruiwu Liu and Kit Lam and Jan Nolta and Junjing Jia and Brian Panganiban and Liping Meng and Ping Zhou and Mohammad Shahnazari and Ritchie, {Robert O.} and Lane, {Nancy E}",
year = "2012",
month = "3",
doi = "10.1038/nm.2665",
language = "English (US)",
volume = "18",
pages = "456--462",
journal = "Nature Medicine",
issn = "1078-8956",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Directing mesenchymal stem cells to bone to augment bone formation and increase bone mass

AU - Guan, Min

AU - Yao, Wei

AU - Liu, Ruiwu

AU - Lam, Kit

AU - Nolta, Jan

AU - Jia, Junjing

AU - Panganiban, Brian

AU - Meng, Liping

AU - Zhou, Ping

AU - Shahnazari, Mohammad

AU - Ritchie, Robert O.

AU - Lane, Nancy E

PY - 2012/3

Y1 - 2012/3

N2 - Aging reduces the number of mesenchymal stem cells (MSCs) that can differentiate into osteoblasts in the bone marrow, which leads to impairment of osteogenesis. However, if MSCs could be directed toward osteogenic differentiation, they could be a viable therapeutic option for bone regeneration. We have developed a method to direct MSCs to the bone surface by attaching a synthetic high-affinity and specific peptidomimetic ligand (LLP2A) against integrin α4β1 on the MSC surface to a bisphosphonate (alendronate, Ale) that has a high affinity for bone. LLP2A-Ale induced MSC migration and osteogenic differentiation in vitro. A single intravenous injection of LLP2A-Ale increased trabecular bone formation and bone mass in both xenotransplantation studies and in immunocompetent mice. Additionally, LLP2A-Ale prevented trabecular bone loss after peak bone acquisition was achieved or as a result of estrogen deficiency. These results provide proof of principle that LLP2A-Ale can direct MSCs to the bone to form new bone and increase bone strength.

AB - Aging reduces the number of mesenchymal stem cells (MSCs) that can differentiate into osteoblasts in the bone marrow, which leads to impairment of osteogenesis. However, if MSCs could be directed toward osteogenic differentiation, they could be a viable therapeutic option for bone regeneration. We have developed a method to direct MSCs to the bone surface by attaching a synthetic high-affinity and specific peptidomimetic ligand (LLP2A) against integrin α4β1 on the MSC surface to a bisphosphonate (alendronate, Ale) that has a high affinity for bone. LLP2A-Ale induced MSC migration and osteogenic differentiation in vitro. A single intravenous injection of LLP2A-Ale increased trabecular bone formation and bone mass in both xenotransplantation studies and in immunocompetent mice. Additionally, LLP2A-Ale prevented trabecular bone loss after peak bone acquisition was achieved or as a result of estrogen deficiency. These results provide proof of principle that LLP2A-Ale can direct MSCs to the bone to form new bone and increase bone strength.

UR - http://www.scopus.com/inward/record.url?scp=84858002781&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84858002781&partnerID=8YFLogxK

U2 - 10.1038/nm.2665

DO - 10.1038/nm.2665

M3 - Article

VL - 18

SP - 456

EP - 462

JO - Nature Medicine

JF - Nature Medicine

SN - 1078-8956

IS - 3

ER -